erlotinib

erlotinib

美 　英

• 網絡埃羅替尼；厄洛替尼；厄羅替尼

例句

A recent phase III trial of the combination of gemcitabine with erlotinib was associated with a significant prolongation of survival .

一項最新的III期試驗顯示吉西他濱聯合厄羅替尼布可以顯著延長生存期。

How erlotinib exhibits its antineoplastic activity in vivo needs to be further elucidated.

厄洛替尼在體內是如何發揮抗腫瘤活性的機制需要進一步闡釋。

One patient of each cohort required dose reduction of erlotinib, both due to skin rash.

2組患者中均有1名患者因為皮疹需要減少厄羅替尼布劑量。

The addition of erlotinib to gemcitabine shows a small but significant improvement in overall survival (OS) versus gemcitabine alone.

與單獨進行吉西他濱治療相比較，增加補充厄洛單抗的治療結果顯示所有存活者（OS）可獲得一個小的但是明顯的改善。

Preliminary results of phase III trial in pancreatic cancer revealed an improvement in survival with the addition of erlotinib.

三期臨床試驗的初步結果揭示了加用厄洛替尼之后患者生存率的提高。

ObjectiveTo evaluate the efficacy, clinical benefits and toxicities of gemcitabine combined with erlotinib for advanced pancreatic cancer.

目的觀察吉西他濱聯合厄洛替尼方案治療進展期胰腺癌的療效、臨床獲益反應和毒性反應。

These findings provide evidence for the inhibitive activity of erlotinib in pancreatic cancer cells.

這些成果為厄洛替尼對胰腺癌細胞的抑制作用提供了證據。

Erlotinib is also being evaluated in combination with capecitabine in patients who failed first-line therapy with gemcitabine .

厄羅替尼布聯合卡培他濱同樣用于一線藥物吉西他濱治療失敗的患者。

In vivo, erlotinib treated mice demonstrated a reduced tumor volume and weight as compared with control.

在體內，厄洛替尼對小鼠的治療作用體現為與對照組相比腫瘤體積和重量的減小。

This study investigated the growth inhibitory effects of erlotinib in pancreatic cancer cells in vitro and in vivo.

本研究探尋了厄洛替尼在體內和體外對胰腺癌細胞生長的抑制效應。

The response rate to erlotinib therapy was similar in patients with tumor-only mutations and in those with tumor and serum mutations (67%).

對埃羅替尼治療的反應率，僅在腫瘤組織中存在變異的患者和那些腫瘤和血漿中均存在變異的患者是相似的（67%）。

The maximum tolerated dose of erlotinib during the radiotherapy phase was 50 mg.

放射治療期間厄羅替尼布的耐受劑量為50mg。

Grade 3 or greater elevations of AST were reported in 11 and 8% of patients receiving erlotinib and placebo, respectively.

應用厄羅替尼布和安慰劑組都有11（8%）名患者出現3級或更高的AST升高。

The molecularly targeted anticancer agent: New advances of erlotinib in the treatment of non- small cell lung cancer

分子靶抗癌藥：埃洛替尼治療非小細胞肺癌的新進展

Synergistic Inhibitory Effect of Indomethacin and Erlotinib on the Growth of Pancreatic Cancer Cells

吲哚美辛與埃羅替尼對胰腺癌細胞生長的協同抑制作用

Study evolution on molecular cancer-targeted drug of erlotinib

分子靶向抗癌藥物埃洛替尼的研究進展

Study on chemotherapy of Erlotinib to non small cell lung cancer

埃洛替尼治療非小細胞肺癌的研究

Death from acute interstitial lung disease related to erlotinib: 2 case reports

厄洛替尼引起急性間質性肺病死亡2例